Bayer announced initiation of a phase I clinical trial with BAY3498264, an investigational oral selective Son of Sevenless Homologue 1 (SOS1) inhibitor. The open-label, first-in-human, dose escalation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback